Acumen Pharmaceuticals (ABOS) Total Non-Current Liabilities (2023 - 2025)
Acumen Pharmaceuticals (ABOS) posted Total Non-Current Liabilities of $52.4 million for Q4 2025, up 6.93% sequentially from $49.0 million in Q3 2025, and down 8.11% YoY from $57.0 million in Q4 2024.
Acumen Pharmaceuticals (ABOS) Total Non-Current Liabilities (2023 - 2025) Analysis & Trends
Acumen Pharmaceuticals has reported Total Non-Current Liabilities for 3 years, with the latest figure at $52.4 million in Q4 2025.
- Quarterly Total Non-Current Liabilities fell 8.11% year-over-year to $52.4 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $52.4 million (down 8.11% YoY) and the FY2025 annual result came in at $52.4 million, down 8.11% from the prior year.
- Total Non-Current Liabilities climbed to $52.4 million in Q4 2025 per ABOS's latest filing, from $49.0 million in the prior quarter.
- Over five years, Total Non-Current Liabilities peaked at $57.0 million in Q4 2024 and troughed at $42.9 million in Q4 2023.
- A 3-year average of $50.8 million and a median of $50.7 million in 2025 frame the typical range for Total Non-Current Liabilities.
- The sharpest annual moves came in 2024 and 2025: Total Non-Current Liabilities surged 33.03% in 2024, then declined 8.11% in 2025.
- Over 3 years, Total Non-Current Liabilities stood at $42.9 million in 2023, then jumped by 33.03% to $57.0 million in 2024, then retreated by 8.11% to $52.4 million in 2025.
- According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $52.4 million, $49.0 million, and $54.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.93 Bn | 131.08 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 86.11 Bn | 78.11 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 65.43 Bn | 60.25 Bn | 1.37 Bn | 40.00 Mn |
| 4 | Moderna | 56.09 Bn | 50.96 Bn | 52.00 Mn | 3.92 Bn |
| 5 | BeOne Medicines | 42.13 Bn | 37.03 Bn | 1.53 Bn | 1.88 Bn |
| 6 | Alnylam Pharmaceuticals | 31.61 Bn | 28.30 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 27.68 Bn | 9.29 Bn | 668.28 Mn | 724.15 Mn |
| 8 | Insmed | 27.49 Bn | 26.32 Bn | 358.27 Mn | 1.17 Bn |
| 9 | Royalty Pharma | 27.36 Bn | 26.52 Bn | - | 9.32 Bn |
| 10 | Acumen Pharmaceuticals | 228.31 Mn | 228.31 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 52.40 Mn |
| Sep 30, 2025 | 49.01 Mn |
| Jun 30, 2025 | 54.74 Mn |
| Mar 31, 2025 | 48.84 Mn |
| Dec 31, 2024 | 57.03 Mn |
| Dec 31, 2023 | 42.87 Mn |